Financial Data and Key Metrics Changes - For the full year 2025, the company reported revenue of $175 million, a decline of approximately 5% compared to $185 million in 2024 [12][16] - Adjusted EBITDA for the full year was $40 million, down from $43 million in 2024 [17] - The company ended the year with $62 million in cash, reflecting an almost 20% increase from the end of 2024 [4] Business Line Data and Key Metrics Changes - Revenue for the fourth quarter was $43 million, a decline of 10% year-over-year [12] - Average paying clients in the fourth quarter were 5,120, down approximately 2% year-over-year and sequentially [13] - Average revenue per paying client for both the fourth quarter and the full year was approximately $2,800, down from prior year levels [15] Market Data and Key Metrics Changes - The company experienced severe pricing compression and competition from illicit markets, particularly affecting California and Michigan, where total retail sales and average retail prices declined year-over-year [12] - Encouraging growth was noted in newer markets such as New York and Ohio, where client penetration was prioritized [13] Company Strategy and Development Direction - The company remains focused on enhancing product offerings and deepening relationships with large California-based clients and MSO partners [6] - Investments are planned across teams and technology to build for the future of Weedmaps [7] - The company is cautious about the potential impact of Schedule III on its business model, emphasizing the need for full legalization [9] Management's Comments on Operating Environment and Future Outlook - The management highlighted that many industry dynamics affecting clients in 2025 are expected to persist into 2026, with first quarter revenue anticipated to decline sequentially by mid- to high-single digits from the fourth quarter [17][18] - The company is committed to preserving financial flexibility and disciplined capital allocation while assessing future opportunities [18] Other Important Information - Total operating expenses for the full year increased modestly by 2% to $174 million, primarily due to certain non-recurring items [16] - A non-cash asset impairment charge of approximately $7.8 million was recorded in the fourth quarter, largely related to goodwill [16] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.

Core Viewpoint - THC Therapeutics, Inc. has acquired The Headquarters Group, Inc. in an all-share transaction valued at approximately $11 million, aiming to create a powerful and flexible player in the legal cannabis industry [1][2][4] Company Overview - THC Therapeutics, Inc. focuses on acquiring and operating a portfolio of synergistic assets within the legal cannabis industry, with a bi-coastal strategy for rapid growth in cultivation, manufacturing, and distribution [9] - The Headquarters Group, Inc. is a holding company with a portfolio that includes companies in genetics, cultivation, extraction, distribution, specialty real estate, and nutrients for cannabis growers, generating combined revenue of approximately $4.8 million [2][7] Strategic Implications - The acquisition is part of THC Therapeutics' strategy to build a fully integrated vertical cannabis platform, enhancing operational efficiencies and revenue generation [3][5] - The combined expertise of over 60 years in cannabis operations management positions the new entity to capitalize on growth opportunities in California and Oregon, with plans to expand into other U.S. states and international markets [4][6] Market Context - The cannabis market is currently experiencing growth, with a strong consolidation phase in the supporting industry, making it an opportune time for strategic partnerships and acquisitions [6] - The focus on efficiency in the cannabis sector is expected to drive values and returns, as companies leverage proven systems and access to capital for further growth [6]